Quanterix Corporation (QTRX)
| Bid | 4.94 |
| Market Cap | 254.37M |
| Revenue (ttm) | 137.82M |
| Net Income (ttm) | -39.75M |
| EPS (ttm) | -1 |
| PE Ratio (ttm) | -6.56 |
| Forward PE | -11 |
| Analyst | Buy |
| Ask | 8.35 |
| Volume | 178,504 |
| Avg. Volume (20D) | 805,726 |
| Open | 6.94 |
| Previous Close | 6.77 |
| Day's Range | 6.49 - 6.71 |
| 52-Week Range | 6.30 - 23.86 |
| Beta | 1.33 |
About QTRX
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in variou...
Analyst Forecast
According to 4 analyst ratings, the average rating for QTRX stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 159.15% from the latest price.
Stock Forecasts
3 weeks ago · businesswire.com
Quanterix Highlights Compelling Benefits of Akoya Biosciences AcquisitionBILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) (“Quanterix” or the “Company”), a company fueling scientific discovery through ultra-sensitive biomarker detection, today reiter...
